# GeneMind Biosciences Co.

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/genemind-biosciences-co

- Industry: Biotechnology
- Headquarters: Shenzhen, China
- Website: www.genemind.com
- Total disclosed funding: $303M
- Latest round: Series D (Sep 14, 2026)
- Investors on record: 28

## About

Founded in 2012 and based in Guangdong, China, GeneMind Biosciences Co., Ltd. is a biotechnology company that focuses on gene sequencing services. The chairman of the board, founder, and chief executive officer, Dr. Yan Qin, graduated from the University Of Science and Technology Of China. The company has acquired and applied more than 500 patents. In November 2022, it released the gene sequencing platform FASTASeq 300. In March 2023, it cooperated with Nanjing Jiangbei New District and landed the R&D and industrialization project of high-throughput gene sequencers and supporting reagents. In September 2026, it raised nearly CNY 600 million in a Series D funding round.

GeneMind Biosciences Co., Ltd.'s main products have a high-throughput DNA sequencing platform and single-molecule DNA sequencer. It has the design and development capability of the modules of sequencing systems, such as high-resolution optical systems, precision fluid control systems, chemical reagents, sequencing chips, and bio-credit software. The annual capacity of sequencers is 1,000 units, and the annual capacity of kits reaches 2.4 million doses. The company also focuses on the fields of non-invasive prenatal testing, preimplantation genetic tests, genetic disease screening and diagnosis, cancer molecular diagnosis, and pathogen detection. 

The company generates revenue by developing and providing gene sequencer and supporting reagents.

The company will use the Series D funding to drive technological innovation, industrial-scale delivery, and global market expansion, so as to to further enrich its portfolio of life science tools—including sequencing and multi-omics solutions, and to strategically position the company at the intersection of AI and the life sciences.

## Funding rounds

- Series D, Sep 14, 2026, $89M — Shanghai International Group, Shenzhen HTI, China Reform Holdings, Delian Capital, Guosheng Securities, Guangxi Beibu Gulf Private Equity Management, Shenzhen Capital Real Estate Fund, Renxian Equity Fund, Hunan Chasing Fund Management, Changsha Shengwei Rongquan Venture Capital, Voyagers Capital, XJSCI, Changzhou Shuangye Venture Capital
- Series C, May 28, 2025, $39M — Guangzhou Kingmed Diagnostics Group Co., Ltd., Sansure Biotech Inc., Jinyuan Kuntong Equity Investment Management, Shengwei Rongquan Capital, Voyagers Capital, Chengdu Qianhe Private Equity Fund Management, Changzhou Shuangye Venture Capital, Haikou Junxin
- Series C, Aug 2, 2023, $56M — Shenzhen HTI, Changde Yuanli Industry Investment Holdings, Shanghai Guoxin Venture Capital Investment, Guangzhou Jinyu Investment and Consulting Co.,Ltd, National Innovation Center for High Performance Medical Devices, Changzhou Shuangye Venture Capital
- Series B, Sep 15, 2021, $63M — Cowin Capital, Sansure Biotech Inc., Shenzhen Qianhai Kexi Capital Management
- Series B, Sep 29, 2020, $21M — Sincere Capital
- Series A, Apr 19, 2018, $35M — Xiyi Asset Management, Tongsheng Equity Investment, Renxian Equity Fund

## Investors

- Xiyi Asset Management (https://capitalatlas.ai/funds/xiyi-asset-management) — Series A
- Tongsheng Equity Investment (https://capitalatlas.ai/funds/tongsheng-equity-investment) — Series A
- Renxian Equity Fund (https://capitalatlas.ai/funds/renxian-equity-fund) — Series A, Series D
- Sincere Capital (https://capitalatlas.ai/funds/sincere-capital) — Series B
- Cowin Capital (https://capitalatlas.ai/funds/cowin-capital) — Series B
- Sansure Biotech Inc. — Series B, Series C
- Shenzhen Qianhai Kexi Capital Management (https://capitalatlas.ai/funds/shenzhen-qianhai-kexi-capital-management) — Series B
- Shenzhen HTI (https://capitalatlas.ai/funds/shenzhen-hti) — Series C, Series D
- Changde Yuanli Industry Investment Holdings — Series C
- Shanghai Guoxin Venture Capital Investment — Series C
- Guangzhou Jinyu Investment and Consulting Co.,Ltd — Series C
- National Innovation Center for High Performance Medical Devices — Series C
- Changzhou Shuangye Venture Capital — Series C, Series D
- Guangzhou Kingmed Diagnostics Group Co., Ltd. — Series C
- Jinyuan Kuntong Equity Investment Management (https://capitalatlas.ai/funds/jinyuan-kuntong-equity-investment-management) — Series C
- Shengwei Rongquan Capital — Series C
- Voyagers Capital (https://capitalatlas.ai/funds/voyagers-capital) — Series C, Series D
- Chengdu Qianhe Private Equity Fund Management — Series C
- Haikou Junxin — Series C
- Shanghai International Group — Series D
- China Reform Holdings (https://capitalatlas.ai/funds/china-reform-holdings) — Series D
- Delian Capital (https://capitalatlas.ai/funds/delian-capital) — Series D
- Guosheng Securities — Series D
- Guangxi Beibu Gulf Private Equity Management (https://capitalatlas.ai/funds/guangxi-beibu-gulf-private-equity-management) — Series D
- Shenzhen Capital Real Estate Fund (https://capitalatlas.ai/funds/shenzhen-capital-real-estate-fund) — Series D
- Hunan Chasing Fund Management (https://capitalatlas.ai/funds/hunan-chasing-fund-management) — Series D
- Changsha Shengwei Rongquan Venture Capital (https://capitalatlas.ai/funds/changsha-shengwei-rongquan-venture-capital) — Series D
- XJSCI — Series D